{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.87","upperLimit":"28.0","value":"8.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"In vivo cellular kinetics of CD3+/CTL019+ levels tisagenlecleucel cells detected by flow cytometry base on best overall response (BOR). The cellular kinetic parameters were estimated from the percentages of CD3+/CTL019+ cells obtained from flow cytometry. Flow cytometry measures the surface expression of chimeric antigen receptors (CARs) on T cells.","dispersionType":"Full Range","groups":[{"description":"All participants who were enrolled in the study","id":"OG000","title":"CTL019"}],"paramType":"MEDIAN","populationDescription":"Cellular Kinetic Analysis Set (CKAS) consisted of participants in the interim efficacy analysis set (IEAS) or efficacy analysis set (EAS) (at time of the interim and primary analysis respectively) who provided an evaluable cellular kinetic profile (at least one cellular kinetic parameter).","reportingStatus":"POSTED","timeFrame":"From pre-dose until 60 months after infusion","title":"Summary of Exposure of CD3+ Tisagenlecleucel Cells in Peripheral Blood for Tmax","type":"SECONDARY","unitOfMeasure":"days"}